FY2025 Earnings Estimate for Zoetis Issued By Zacks Research

Zoetis Inc. (NYSE:ZTS) – Analysts at Zacks Research cut their FY2025 earnings per share estimates for Zoetis in a note issued to investors on Wednesday, January 8th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $6.36 per share for the year, down from their previous estimate of $6.37. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Zacks Research also issued estimates for Zoetis’ Q4 2025 earnings at $1.59 EPS, Q4 2026 earnings at $1.79 EPS and FY2026 earnings at $6.97 EPS.

A number of other analysts have also recently commented on ZTS. UBS Group initiated coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus decreased their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday. JPMorgan Chase & Co. raised their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Leerink Partners began coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $211.89.

Zoetis Trading Up 0.9 %

Shares of ZTS stock opened at $164.93 on Friday. The stock has a market cap of $74.41 billion, a price-to-earnings ratio of 31.00, a PEG ratio of 2.91 and a beta of 0.89. Zoetis has a 1-year low of $144.80 and a 1-year high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a 50-day moving average of $172.08 and a 200-day moving average of $180.20.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm earned $1.36 EPS.

Institutional Trading of Zoetis

Several institutional investors and hedge funds have recently made changes to their positions in ZTS. Darwin Wealth Management LLC bought a new stake in Zoetis during the third quarter worth about $31,000. First Personal Financial Services bought a new stake in Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP purchased a new stake in Zoetis during the 3rd quarter valued at $33,000. Dunhill Financial LLC grew its holdings in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. Finally, Quarry LP increased its position in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.